Astra Zeneca Starts Japan Development Of Pediatric Nexium
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca Japan will begin the development of the PPI Nexium (esomeprazole magnesium hydrate) for use in children aged one to 14, the subsidiary announced on July 15.